1) Strategy & Leadership
- Merck continues to execute its strategy effectively, with a focus on new product launches and clinical milestones that enhance the long-term potential of its pipeline.
- The company is confident in its ability to deliver long-term value for both patients and shareholders, emphasizing disciplined execution over the past years.
- Leadership expressed optimism about the future, highlighting the ongoing transformation of the business and the visibility into the emerging product portfolio.

2) Financial & Segment Results
- Q3 2026 revenues reached $18.1 billion, a 5% increase YoY (4% excluding foreign exchange impacts).
- Key product performance:
- KEYTRUDA family: Sales increased 6% to $8.6 billion, driven by strong demand in earlier-stage cancers and metastatic indications.
- Gardasil: Sales of $2 billion, up 14%, with U.S. sales growing 18% due to a significant CDC purchase.
- WINREVAIR: Sales surged 94% to $694 million, reflecting strong demand in pulmonary arterial hypertension.
- Operating expenses rose 12% to $7.4 billion, attributed to investments in product launches and pipeline advancement.

3) Operational & Product Plans
- Significant clinical milestones were achieved, particularly in oncology, with promising Phase III results for sac TMT in endometrial cancer and positive data for a therapeutic cancer vaccine in melanoma.
- The company is advancing its pipeline across multiple therapeutic areas, including immunology and ophthalmology, with several important studies and regulatory submissions expected in the coming year.
- Merck plans to continue investing in its pipeline and product launches to drive long-term growth.

4) Guidance & Outlook
- Merck has raised its full-year revenue guidance to a range of $66.8 billion to $67.3 billion, reflecting a growth of 3% to 4%.
- EPS guidance is now projected between $2.77 and $2.82, incorporating a positive impact from foreign exchange.
- For 2027, moderate revenue growth is anticipated, with headwinds from generic competition and the loss of exclusivity for certain products, but the company expects to return to strong growth thereafter.

5) Problems / Headwinds
- The company faces challenges from the impending loss of exclusivity for KEYTRUDA and other products, which may impact revenue growth in the near term.
- There are ongoing litigation issues regarding the subcutaneous formulation of KEYTRUDA (QLEX) in Europe, which could affect market access in certain regions.
- The impact of market dynamics, such as increased vaccine hesitancy and competition from generics, is being closely monitored.

Bottom line: Merck's strong Q3 performance, driven by new product contributions and strategic execution, positions the company well for future growth despite facing headwinds from patent expirations and market competition. The ongoing investment in its pipeline and product launches underlines its commitment to delivering long-term value for shareholders.